Astellas, Medivation's Xtandi shows significant benefit in pre-chemo prostate cancer patients
This article was originally published in Scrip
Executive Summary
Astellas Pharma and Medivation’s prostate cancer drug Xtandi showed a significant benefit by extending lives and preventing the disease from worsening in patients who were not yet treated with chemotherapy, new data show.